A year-long study of Elinzanetant (Lynkuet) reveals lasting relief from hot flashes and improved sleep without hormones. Here’s what you need to know about this breakthrough non-hormonal option.
Elinzanetant (Lynkuet) is a new non-hormonal therapy under FDA review that could finally provide relief from hot flashes for women who can’t or prefer not to take hormone therapy. Promising trial results offer hope for midlife symptom relief.
Fezolinetant (Veozah) is the first non-hormonal drug approved to tackle menopausal hot flashes—but a rare liver injury warning means careful monitoring is essential. Could this new option finally provide relief for women who can’t or don’t want hormone therapy?
A major 2024 review of the Women’s Health Initiative has rewritten the story on hormone therapy. For women under 60 or within 10 years of menopause, the benefits may outweigh the risks—marking a turning point in how doctors and patients approach treatment.
A major study reveals women’s heart health declines rapidly after menopause, making this a crucial time for screening, prevention, and awareness.
Could menopause one day be optional? Scientists are exploring radical new ways to delay or even prevent it, from ovarian tissue freezing to groundbreaking hormonal research.